Date: 2014-10-29
Type of information: Capital increase
Company: Bavarian Nordic (Denmark)
Investors: Johnson & Johnson Development Corporation (USA - NJ)
Amount: DKK 250,999,997.35 (€ 33.7 million)
Funding type: capital increase
Planned used:
Others: * On October 29, 2014, Bavarian Nordic announced the completion of the direct placement of 1,331,984 new shares of nominal value DKK 10 each (corresponding to approximately 4.85% of the Company\'s share capital after completion of the direct placement) in Bavarian Nordic at a subscription price of DKK 188.4407 per new share to JJDC, raising gross proceeds to Bavarian Nordic of DKK 250,999,997.35. The direct placement, which is made in connection with the license and supply agreement for the Company\'s MVA-BN® vector in respect of Ebola between Bavarian Nordic and Crucell Holland B.V., one of the Janssen Pharmaceutical companies of Johnson & Johnson, was originally announced on 22 October 2014.Bavarian Nordic\'s share capital will amount to DKK 274,448,470 after registration of the capital increase with the Danish Business Authority. It is expected that the new shares will be admitted to trading and official listing on Nasdaq Copenhagen on 31 October 2014.
Therapeutic area: Infectious diseases
